Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.0014 USD
Change Today -0.0002 / -12.50%
Volume 7.6M
ADMD On Other Exchanges
As of 8:10 PM 10/8/15 All times are local (Market data is delayed by at least 15 minutes).

advanced medical isotope cor (ADMD) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/13/15 - $0.0064
52 Week Low
12/9/14 - $0.0001
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

advanced medical isotope cor (ADMD) Related Businessweek News

No Related Businessweek News Found

advanced medical isotope cor (ADMD) Details

Advanced Medical Isotope Corporation develops brachytherapy devices for therapeutic applications. Its brachytherapy products include yttrium-90 RadioGel device, which combines Y-90 particles with a polymer carrier that injects directly into the tumor; yttrium-90 Fast-Resorbable Polymer Seeds, which is used in place of treating cancers with marketed titanium or glass seeds; and yttrium-90 Polymer Topical Paste that is used to treat residual tumor cells. The company’s customers for stable isotopes include a range of hospitals, universities, research centers, and national laboratories, as well as academic and government institutions in the United States and internationally. Advanced Medical Isotope Corporation was incorporated in 1994 is based in Kennewick, Washington.

4 Employees
Last Reported Date: 04/21/15
Founded in 1994

advanced medical isotope cor (ADMD) Top Compensated Officers

Co-Founder, Chairman and Chief Executive Offi...
Total Annual Compensation: $250.0K
Chief Financial Officer
Total Annual Compensation: $200.4K
Compensation as of Fiscal Year 2014.

advanced medical isotope cor (ADMD) Key Developments

Advanced Medical Isotope Corporation announced delayed 10-Q filing

On 08/14/2015, Advanced Medical Isotope Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Advanced Medical Isotope Corporation Provides Update on the Y-90 RadioGel Device de novo Submission to United States Food and Drug Administration

Advanced Medical Isotope Corporation provided an update on the Y-90 RadioGel(TM) device de novo submission to the United States Food and Drug Administration as well as an update on financial matters. In late December 2014, the Company provided the FDA with a de novo submission for the Y-90 RadioGel(TM) device requesting reclassification as a Class II device and marketing clearance. The Company has been notified by the FDA that it has declined the de novo request for Class II designation for the AMIC Y-90 RadioGel(TM) device and that it remains in Class III (Premarket Approval). In the correspondence from the FDA, the FDA requested additional data be generated to evaluate the safety and effectiveness of the Y-90 RadioGel(TM) device and provided a framework for submission of a new direct de novo. As part of this process, AMIC is working with its partners to establish protocols for preclinical animal studies as suggested by the FDA. AMIC anticipates using the Pre-Submission process to meet with the FDA in the 4th quarter to review the draft protocols for the preclinical studies and to generate additional feedback in support of a new direct de novo filing seeking reclassification as a Class II device and accordingly, marketing clearance. The Company's primary focus continues to be obtaining regulatory clearance by the FDA of the Y-90 RadioGel(TM) device. In addition, AMIC is evaluating the requirements for regulatory approval for the Y-90 RadioGel(TM) device in Europe, Canada and Asia as well as for use in the veterinary market as additional paths toward commercial use of the device. AMIC intends to pursue an uplisting transaction as part of its financial recapitalization plan to raise the capital necessary to complete the direct de novo FDA filing for the Y-90 RadioGel(TM) device and to pursue commercialization and partnering efforts. The Company expects that its known data from previous bench and animal studies in combination with the preclinical studies that the FDA is requesting will support a Class II designation and therefore, marketing clearance.

Advanced Medical Isotope Corporation Accepts Resignation of Kenin M. Spivak as Member of the Board

On April 14, 2015, the Board of Directors of Advanced Medical Isotope Corporation received and accepted the resignation of Kenin M. Spivak from his position as a member of the Board of AMIC. Mr. Spivak's decision to resign was related to time commitments on other projects that could interfere with his ability to timely perform his responsibilities as a director, and was not the result of any disagreement with the Company on the company's operation, policies or practices. Mr. Spivak was also party to a business advisory agreement with the AMIC. This agreement is currently being reevaluated for modification by the Company in light of Mr. Spivak's other time commitments.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADMD:US $0.00 USD -0.0002

ADMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ADMD.
View Industry Companies

Industry Analysis


Industry Average

Valuation ADMD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 184.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADVANCED MEDICAL ISOTOPE COR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at